Tomohiro Tatsuta
Hyogo College of Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tomohiro Tatsuta.
Neuroscience | 2007
Junichi Kitanaka; Nobue Kitanaka; Tomohiro Tatsuta; Yoshio Morita; Motohiko Takemura
The administration of methamphetamine (METH, 10 mg/kg, i.p.) to male ICR mice induced stereotyped behavior consisting of nail and/or wood chip biting (86.0%), continuous sniffing (12.0%), head bobbing (1.1%), and circling (1.0%) during the observation period of 1 h. Pretreatment of the mice with metoprine (2, 10, and 20 mg/kg, i.p.), a selective inhibitor of histamine N-methyltransferase (HMT), which metabolizes histamine in the brain, significantly increased and decreased METH-induced continuous sniffing (20.5, 51.3, and 80.3%) and nail and/or wood chip biting (77.4, 45.3, and 14.2%), respectively, in a dose-dependent manner. The hypothalamic contents of histamine and its metabolite N(tau)-methylhistamine were significantly increased and decreased by metoprine (10 mg/kg, i.p.), respectively. The metoprine action on METH-induced behavior was completely abolished by pyrilamine (10 and 20 mg/kg) and ketotifen (10 mg/kg), selective, centrally acting histamine H(1) receptor antagonists, but not by fexofenadine (20 mg/kg), zolantidine (10 mg/kg) and thioperamide (10 mg/kg), a peripherally acting histamine H(1) receptor antagonist and a selective, brain-penetrating antagonist for histamine H(2) and H(3) receptors, respectively. The metoprine action was mimicked by SKF 91488 (100 microg/animal, i.c.v.), another HMT inhibitor, and the action of SKF 91488 was also blocked by pyrilamine. The frequency of the expression of METH-induced total stereotypic patterns was unchanged after metoprine pretreatment. Mice pretreated with metoprine displayed no anxiety-like behavior in the elevated plus maze test. These results suggest that brain histamine, increased by agents such as metoprine and SKF 91488, binds to histamine H(1) receptors in the brain, resulting in the modulation of dopaminergic transmission associated with stereotyped behavioral patterns induced by METH.
Pharmacology, Biochemistry and Behavior | 2007
Tomohiro Tatsuta; Nobue Kitanaka; Junichi Kitanaka; Yoshio Morita; Motohiko Takemura
The effects of topiramate, a structurally novel anticonvulsant, on the methamphetamine (METH)-induced expression of stereotypy and conditioned place preference (CPP) in male ICR mice were investigated. After a single administration of METH (10 mg/kg, i.p.), mice showed stereotyped behaviors with a plateau level 25 min after drug challenge. Pretreatment with topiramate (1, 10, and 100 mg/kg, i.p.) 30 min prior to METH challenge had no effect on the expression frequency of stereotypy, compared with saline challenge. No differential effects of topiramate on METH-induced stereotyped behavior (that is, head-bobbing, circling, continuous sniffing, nail and/or wood-chip biting, and vigorous and compulsive grooming) were observed. In saline-challenged groups, the doses of topiramate examined did not induce any stereotyped behaviors. Although mice showed a significant CPP for METH (0.5 mg/kg, i.p.), pretreatment with subchronic topiramate did not affect the magnitude of CPP. Locomotor activity was not affected by the doses of topiramate tested. Conditioned rewarding or aversive effects of topiramate were not observed as indexed by the place preference procedure. These results suggested the lack of effect of topiramate on METH-induced stereotypy and rewarding property in mice.
Synapse | 2008
Nobue Kitanaka; Junichi Kitanaka; F. Scott Hall; Tomohiro Tatsuta; Yoshio Morita; Motohiko Takemura; Xiao-Bing Wang; George R. Uhl
Neuronal adaptations have been found to occur in multiple brain regions after chronic intake of abused drugs, and are therefore thought to underlie drug dependence, tolerance, and withdrawal. Pathophysiological changes in drug responsiveness as well as behavioral sequelae of chronic drug exposure are thought to depend largely upon the altered state of heterotrimeric GTP binding protein (G protein)‐coupled receptor (GPCR)‐G protein interactions. Responsiveness of GPCR‐related intracellular signaling systems to drugs of abuse is heterogeneous, depending on the types of intracellular effectors to which the specific Gα protein subtypes are coupled and GPCR‐G protein coupling efficiency, factors influenced by the class of drug, expression levels of G protein subunits, and drug treatment regimens. To enhance understanding of the molecular mechanisms that underlie the development of pathophysiological states resulting from chronic intake of abused drugs, this review focuses on alterations in the expression levels of G protein subunits induced by various drugs of abuse. Changes in these mechanisms appear to be specific to particular drugs of abuse, and specific conditions of drug treatment. Synapse 62:689‐699, 2008.
Pharmacology, Biochemistry and Behavior | 2010
Junichi Kitanaka; Nobue Kitanaka; Tomohiro Tatsuta; Akio Miyoshi; Atena Koumoto; Koh-ichi Tanaka; Nobuyoshi Nishiyama; Yoshio Morita; Motohiko Takemura
The administration of methamphetamine (METH; 10mg/kg, i.p.) to male ICR mice induced bizarre behaviors including persistent locomotion and stereotypical behaviors, which were classified into four categories: stereotypical head-bobbing, circling, sniffing, and biting. Pretreatment with l-histidine (750 mg/kg, i.p.) significantly decreased the stereotypical biting induced by METH and significantly increased persistent locomotion. This effect of l-histidine on behavior was completely abolished by simultaneous administration of pyrilamine or ketotifen (brain-penetrating histamine H(1) receptor antagonists; 10mg/kg each, i.p.), but not by the administration of fexofenadine (a non-sedating histamine H(1) receptor antagonist that does not cross the blood-brain barrier; 20mg/kg), zolantidine (a brain-penetrating histamine H(2) receptor antagonist; 10mg/kg), thioperamide, or clobenpropit (brain-penetrating histamine H(3) receptor antagonists; 10mg/kg each). The histamine content of the hypothalamus was significantly increased by l-histidine treatment. These data suggest that l-histidine modifies the effects of METH through central histamine H(1) receptors.
Pharmacology, Biochemistry and Behavior | 2005
Junichi Kitanaka; Nobue Kitanaka; Tomohiro Tatsuta; Motohiko Takemura
2-Phenylethylamine (PEA)-induced stereotypy in rodents is suggested to model psychotic symptoms of schizophrenia. It is reported that PEA induces dopamine release in the striatum in vivo and in vitro. The present study analyzed the PEA-induced stereotypy and possible associated brain dopamine metabolism in mice. Using male ICR mice treated with a combination of PEA (100 mg/kg, i.p.) and increasing doses of l-deprenyl (0-10 mg/kg, s.c.), we examined (1) the behavioral profile of stereotypy (rating the scores), and (2) the tissue levels of dopamine and its metabolites by high-performance liquid chromatography. The stereotypic scores reached a plateau level at 10 min which lasted until 30 min after a single administration of 100 mg/kg PEA. The stereotyped behavior completely disappeared 45 min after PEA administration. Pretreatment with l-deprenyl (0.1, 1, and 10 mg/kg, s.c.) dose-dependently prolonged the duration of PEA-induced stereotypy. Notably, pretreatment with l-deprenyl dose-dependently increased the continuous sniffing. Treatment with PEA in combination of l-deprenyl (1 and 10 mg/kg) significantly reduced the level of dopamine in the region of the striatum and nucleus accumbens, compared with control animals. These results suggest that PEA in combination with l-deprenyl prolonged the duration of the stereotypy (particularly, continuous sniffing) while reducing the striatal level of dopamine.
Brain Research | 2012
Nobue Kitanaka; Junichi Kitanaka; F. Scott Hall; George R. Uhl; Kaname Watabe; Hitoshi Kubo; Hitoshi Takahashi; Tomohiro Tatsuta; Yoshio Morita; Motohiko Takemura
Repeated intermittent administration of amphetamines acutely increases appetitive and consummatory aspects of motivated behaviors as well as general activity and exploratory behavior, including voluntary running wheel activity. Subsequently, if the drug is withdrawn, the frequency of these behaviors decreases, which is thought to be indicative of dysphoric symptoms associated with amphetamine withdrawal. Such decreases may be observed after chronic treatment or even after single drug administrations. In the present study, the effect of acute methamphetamine (METH) on running wheel activity, horizontal locomotion, appetitive behavior (food access), and consummatory behavior (food and water intake) was investigated in mice. A multi-configuration behavior apparatus designed to monitor the five behaviors was developed, where combined measures were recorded simultaneously. In the first experiment, naïve male ICR mice showed gradually increasing running wheel activity over three consecutive days after exposure to a running wheel, while mice without a running wheel showed gradually decreasing horizontal locomotion, consistent with running wheel activity being a positively motivated form of natural motor activity. In experiment 2, increased horizontal locomotion and food access, and decreased food intake, were observed for the initial 3h after acute METH challenge. Subsequently, during the dark phase period decreased running wheel activity and horizontal locomotion were observed. The reductions in running wheel activity and horizontal locomotion may be indicative of reduced dopaminergic function, although it remains to be seen if these changes may be more pronounced after more prolonged METH treatments.
Brain Research | 2013
Junichi Kitanaka; Nobue Kitanaka; F. Scott Hall; George R. Uhl; Yuko Fukushima; Tatsuo Sawai; Kaname Watabe; Hitoshi Kubo; Hitoshi Takahashi; Koh Ichi Tanaka; Nobuyoshi Nishiyama; Tomohiro Tatsuta; Yoshio Morita; Motohiko Takemura
We investigated whether pretreatment with opioid receptor antagonists affected methamphetamine (METH)-induced stereotypy in mice. Pretreatment of male ICR mice with naloxone, a relatively non-selective opioid receptor antagonist, significantly attenuated the total incidence of METH-induced stereotypical behavior compared with saline vehicle-pretreated subjects. Furthermore, the distribution of METH-induced stereotypical behavior was affected by naloxone administration. Thus, METH-induced stereotypical sniffing and persistent locomotion were significantly increased by naloxone treatment while stereotypical biting was reduced. One way to interpret this pattern of effects is that pretreatment with naloxone appeared to produce a shift in the dose-response curve for METH. Thus, while the more intense forms of oral-facial stereotypies were reduced, increased persistent locomotion was observed in mice given naloxone followed by METH. The selective μ opioid receptor antagonist β-funaltrexamine, but not nor-binaltorphimine (a κ-selective antagonist) nor naltrindole (a δ-selective antagonist), mimicked the effect of naloxone. These observations suggest that opioid receptor antagonists may attenuate METH-induced stereotypical biting in mice via μ opioid receptors, and suggest that antagonism of this system may be a potential therapeutic approach to reducing some deleterious effects of METH use and perhaps in the treatment of some forms of self-injurious behavior.
Neuroscience Research | 2011
Junichi Kitanaka; Nobue Kitanaka; Hiroki Minami; Masayuki Okamoto; Koh-ichi Tanaka; Tomohiro Tatsuta; Yoshio Morita; Nobuyoshi Nishiyama; Motohiko Takemura
Riluzole, a drug currently used to slow the progression of amyotrophic lateral sclerosis (ALS), directly affects the glutamatergic system. Growing evidence indicated that the glutamatergic neurotransmitter system is central to the neurobiology and treatment of mood and anxiety disorders. It has been reported that many behavioral changes, such as hyperemotional responses and anxiety-like behaviors, observed in olfactory bulbectomy (OBX) of rats were improved by subchronic treatment of antidepressants. Recently, we showed that riluzole attenuated hyperemotional responses in a rat OBX model of depression. The present study examined the effects of riluzole on an anxiety-like behaviors in OBX rats. The olfactory bulbs in rats were removed by suction. Riluzole was administered p.o. once daily. The anxietylike behavior of rats was measured by elevated plus maze test. The OBX rats chronically treated with vehicle for 8 days at 14 days following surgery showed decreases in the time spent on the open arm of a plus-maze. Subchronic riluzole treatment (1–3 mg/kg) in OBX rats significantly increased the time spent on the open arm of the plus-maze, whereas subchronic riluzole treatment (1–10 mg/kg) in OBX rats significantly decreased the time spent on the closed arm of the plus-maze. Subchronic riluzole treatment (10 mg/kg) in sham operated rats had no significant effects on the time spent on both open and closed arms of the plus-maze. On the other hand, total number of entries to closed and open arms were significantly increased in OBX rats by subchronic treatment with riluzole (1–10 mg/kg), whereas no differences was found between vehicle and riluzole subchronic treatment in sham rats. Based on these results, we suggest that riluzole reduces the anxietylike behaviors similarly to hyperemotional responses in OBX rats, an animal model of depression. In conclusion, our results suggest that riluzole could improve symptoms in the mood and anxiety disorders. Research fund: Japan Fundation for Neuroscience and Mental Health.
Neurochemical Research | 2006
Tomohiro Tatsuta; Nobue Kitanaka; Junichi Kitanaka; Yoshio Morita; Motohiko Takemura
Neurochemical Research | 2010
Nobue Kitanaka; Junichi Kitanaka; Tomohiro Tatsuta; Koh-ichi Tanaka; Kaname Watabe; Nobuyoshi Nishiyama; Yoshio Morita; Motohiko Takemura